BCG vaccine - Serum Institute of India/Vakzine Projekt Management
Alternative Names: BCG VPM 1002; BCG-vaccine-Vakzine-Projekt-Management; rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BCLatest Information Update: 17 Feb 2025
At a glance
- Originator Max Planck Institute for Infection Biology
- Developer Max Planck Institute for Infection Biology; Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
- Class COVID-19 vaccines; Tuberculosis vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections; Respiratory tract infections; Tuberculosis
- Phase I/II Bladder cancer
Most Recent Events
- 30 Oct 2024 Serum Institute of India and Vakzine Projekt Management completes a phase-III clinical trials in Tuberculosis (In neonates, Prevention) in Kenya, South Africa, Gabon, Tanzania and Uganda (NCT04351685)
- 12 Oct 2021 Vakzine Projekt Management completes phase III trial in Respiratory tract infections (Prevention) in Germany (Transdermal) (EudraCT2020-001675-33) (NCT04435379)
- 09 Sep 2021 Serum Institute of India completes the phase III COBRA trial in COVID-2019 infections (Prevention) in Canada and India(Intradermal) (NCT04439045)